Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

Native high-density lipoprotein and melatonin improve platelet response induced by glycated lipoproteins

D. Ozsavci, A. Nazli, O. Bingol Ozakpinar, G. Yanikkaya Demirel, B. Vanizor Kural, A. Sener

. 2018 ; 64 (4) : 144-152.

Language English Country Czech Republic

Document type Journal Article

Activated platelets and glycated lipoproteins are responsible for atherothrombosis in diabetics. Melatonin and native high-density lipoproteins are crucial in the preservation of pro/oxidant-antioxidant balance. The aim of the present study was to investigate the in vitro effects of native high-density lipoproteins and melatonin on altering the platelet response induced by glycated lipoproteins. Low-density lipoproteins and high-density lipoproteins were purified from plasma by ultracentrifugation and were glycated with glucose for three weeks. After incubation with or without melatonin/or native highdensity lipoproteins, low-density lipoproteins, glycated low-density lipoproteins/glycated high-density lipoproteins were added to ADP-induced platelets. Oxidative parameters, caspase-3/9 and nitric oxide levels were measured spectrophotometrically; CD62-P/ annexin-V expression was determined by flow cytometry. In glycated low-density lipoprotein/glycated high-density lipoprotein-treated groups, platelet malondialdehyde/ protein carbonyl, P-selectin, annexin-V, caspase-3/9 levels were increased (ranging from P < 0.001 to P < 0.01); glutathione and nitric oxide levels were reduced (ranging from P < 0.001 to P < 0.01). In glycated low-density lipoprotein/glycated high-density lipoprotein-treated groups, melatonin treatment reduced malondialdehyde, protein carbonyl, CD62-P, annexin-V and caspase-3/9 (P < 0.001, P < 0.01) levels and elevated nitric oxide (only glycated low-density lipoproteins). In glycated low-density lipoprotein/glycated high-density lipoprotein-treated groups, native high-density lipoprotein treatment reduced malondialdehyde, protein carbonyl, annexin-V, caspase-3/9 levels (P < 0.001, P < 0.01) and increased glutathione; nitric oxide levels (only with gly-HDL). Both melatonin and high-density lipoproteins should be regarded as novel promising mechanism-based potential therapeutic targets to prevent atherothrombosis in diabetics.

000      
00000naa a2200000 a 4500
001      
bmc19021848
003      
CZ-PrNML
005      
20190614075942.0
007      
ta
008      
190607s2018 xr d f 000 0|eng||
009      
AR
035    __
$a (PubMed)30724160
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xr
100    1_
$a Ozsavci, D. $u Department of Biochemistry, Faculty of Pharmacy, Marmara University, İstanbul, Turkey
245    10
$a Native high-density lipoprotein and melatonin improve platelet response induced by glycated lipoproteins / $c D. Ozsavci, A. Nazli, O. Bingol Ozakpinar, G. Yanikkaya Demirel, B. Vanizor Kural, A. Sener
520    9_
$a Activated platelets and glycated lipoproteins are responsible for atherothrombosis in diabetics. Melatonin and native high-density lipoproteins are crucial in the preservation of pro/oxidant-antioxidant balance. The aim of the present study was to investigate the in vitro effects of native high-density lipoproteins and melatonin on altering the platelet response induced by glycated lipoproteins. Low-density lipoproteins and high-density lipoproteins were purified from plasma by ultracentrifugation and were glycated with glucose for three weeks. After incubation with or without melatonin/or native highdensity lipoproteins, low-density lipoproteins, glycated low-density lipoproteins/glycated high-density lipoproteins were added to ADP-induced platelets. Oxidative parameters, caspase-3/9 and nitric oxide levels were measured spectrophotometrically; CD62-P/ annexin-V expression was determined by flow cytometry. In glycated low-density lipoprotein/glycated high-density lipoprotein-treated groups, platelet malondialdehyde/ protein carbonyl, P-selectin, annexin-V, caspase-3/9 levels were increased (ranging from P < 0.001 to P < 0.01); glutathione and nitric oxide levels were reduced (ranging from P < 0.001 to P < 0.01). In glycated low-density lipoprotein/glycated high-density lipoprotein-treated groups, melatonin treatment reduced malondialdehyde, protein carbonyl, CD62-P, annexin-V and caspase-3/9 (P < 0.001, P < 0.01) levels and elevated nitric oxide (only glycated low-density lipoproteins). In glycated low-density lipoprotein/glycated high-density lipoprotein-treated groups, native high-density lipoprotein treatment reduced malondialdehyde, protein carbonyl, annexin-V, caspase-3/9 levels (P < 0.001, P < 0.01) and increased glutathione; nitric oxide levels (only with gly-HDL). Both melatonin and high-density lipoproteins should be regarded as novel promising mechanism-based potential therapeutic targets to prevent atherothrombosis in diabetics.
650    _2
$a dospělí $7 D000328
650    _2
$a apoptóza $x účinky léků $7 D017209
650    _2
$a aryldialkylfosfatasa $x metabolismus $7 D043303
650    _2
$a trombocyty $x účinky léků $7 D001792
650    _2
$a glutathion $x metabolismus $7 D005978
650    _2
$a glykosylace $x účinky léků $7 D006031
650    _2
$a lidé $7 D006801
650    _2
$a lipoproteiny HDL $x farmakologie $7 D008075
650    _2
$a malondialdehyd $x metabolismus $7 D008315
650    _2
$a melatonin $x farmakologie $7 D008550
650    _2
$a lidé středního věku $7 D008875
650    _2
$a oxid dusnatý $x metabolismus $7 D009569
650    _2
$a oxidace-redukce $7 D010084
650    _2
$a oxidační stres $x účinky léků $7 D018384
650    _2
$a karbonylace proteinů $7 D050050
655    _2
$a časopisecké články $7 D016428
700    1_
$a Nazli, A. $u Department of Biochemistry, Faculty of Pharmacy, Marmara University, İstanbul, Turkey
700    1_
$a Bingol Ozakpinar, O. $u Department of Biochemistry, Faculty of Pharmacy, Marmara University, İstanbul, Turkey
700    1_
$a Yanikkaya Demirel, G. $u Department of Immunology, School of Medicine, Yeditepe University, İstanbul, Turkey
700    1_
$a Vanizor Kural, B. $u Department of Biochemistry, Medical Faculty, Karadeniz Technical University, Trabzon, Turkey
700    1_
$a Sener, A. $u Department of Biochemistry, Faculty of Pharmacy, Marmara University, İstanbul, Turkey
773    0_
$w MED00011004 $t Folia biologica $x 0015-5500 $g Roč. 64, č. 4 (2018), s. 144-152
856    41
$u https://pubmed.ncbi.nlm.nih.gov/30724160 $y Pubmed
856    41
$u https://fb.cuni.cz/file/5879/fb2018a0018.pdf $y plný text volně přístupný
910    __
$a ABA008 $b A 970 $c 89 $y 4 $z 0
990    __
$a 20190607 $b ABA008
991    __
$a 20190614080130 $b ABA008
999    __
$a ok $b bmc $g 1415463 $s 1060203
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2018 $b 64 $c 4 $d 144-152 $i 0015-5500 $m Folia biologica (Praha) $n Folia biol. (Praha) $x MED00011004
LZP    __
$b NLK118 $a Pubmed-20190607

Find record

Citation metrics

Loading data ...

Archiving options

Loading data ...